Carfilzomib From Onyx Gets FDA Approval for Treating Multiple Myeloma For Patients Who Have Had Prior Treatments
Posted Jul 20 2012 6:33pm
Kyprolis is the name of the drug under which it will be marketed. Melanoma is getting some real attention with both drugs and diagnosis devices as well. At ASCO this year melanoma drugs were a big focus as well. BD
From the website: Carfilzomib is a next-generation proteasome inhibitor that is being developed as a potential treatment for patients with multiple myeloma and solid tumors. To date, the agent has generated a positive efficacy signal in multiple clinical studies with an encouraging safety profile, including low rates of neuropathy.
Onyx Pharmaceuticals just went from being a one-drug company, to a two-drug company .
The South San Francisco-based cancer drug developer (NASDAQ: ONXX ) won clearance from the FDA to start selling carfilzomib (Kyprolis) as a new treatment for patients with multiple myeloma, who have gotten at least two prior treatments.
“The approval of Kyprolis provides a treatment option to patients with multiple myeloma whose disease has progressed despite use of available therapies,” said Richard Pazdur, the director of the Office of Hematology and Oncology Products in FDA’s Center for Drug Evaluation and Research, in a statement. “We are encouraged by the continued progress in the development of drugs for multiple myeloma over the past decade, offering improved treatment of this disease.”